secwatch.observer — SEC 8-K summary
======================================

Issuer:     COMPASS Pathways plc (CMPS)
CIK:        0001816590
Form:       8-K
Filed at:   2022-05-10T23:59:59+00:00
Accession:  0001628280-22-013441
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

COMPASS Pathways reports Q1 2022 net loss of $21.2M; cash $243.7M; FDA end-of-phase II meeting held
--------------------------------------------------------------------------------

- Net loss $21.2M ($0.50/sh) vs $12.7M ($0.35) in Q1 2021; R&D expenses $15.4M (up from $6.9M).
- Cash and cash equivalents $243.7M as of March 31, 2022, down from $273.2M at Dec 31, 2021.
- End-of-phase II meeting with FDA completed; finalizing Phase III design for TRD program targeting H2 2022.
- Awarded Innovation Passport under UK MHRA ILAP for COMP360 psilocybin therapy.
- Phase II trial in PTSD ongoing; collaboration with King's College London and NHS for mental health research.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816590/000162828022013441/0001628280-22-013441-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816590/000162828022013441/cmps-20220510.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-013441

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer